Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01372
|
|||||
| Drug Name |
Topiramate
|
|||||
| Synonyms |
Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Partial seizures [ICD11:8A68.0] | Approved | [1] | |||
| Therapeutic Class |
Anticonvulsants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C12H21NO8S
|
|||||
| Canonical SMILES |
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C
|
|||||
| InChI |
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
|
|||||
| InChIKey |
KJADKKWYZYXHBB-XBWDGYHZSA-N
|
|||||
| CAS Number |
CAS 97240-79-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 339.36 | Topological Polar Surface Area | 124 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
-0.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9705
,7847603
,7980814
,11039383
,11484731
,11488944
,11528651
,12013555
,14777895
,14924784
,24724627
,25819957
,26612934
,26719832
,39317930
,46386619
,46508334
,46511457
,47277061
,47425755
,48416647
,48764342
,49681704
,49835829
,50070928
,50123385
,53787612
,57359151
,77351910
,85248100
,92124710
,92307910
,92308459
,93167012
,93167145
,97857519
,99437151
,104109398
,104234233
,104971753
,124658936
,124757247
,124800161
,125164051
,125312450
,126525327
,126606833
,126670104
,128389335
,134337459
|
|||||
| ChEBI ID |
CHEBI:63631
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Topiramate was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009 Nov;26(11):2464-70. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.